CervoMed Inc.
$ 4.80
-5.88%
11 Feb - close price
- Market Cap 47,188,900 USD
- Current Price $ 4.80
- High / Low $ 5.12 / 4.70
- Stock P/E N/A
- Book Value 2.81
- EPS -2.90
- Next Earning Report 2026-03-16
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.43 %
- ROE -0.71 %
- 52 Week High 16.94
- 52 Week Low 1.92
About
CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of drug treatments for neurodegenerative diseases. The company is headquartered in Boston, Massachusetts.
Analyst Target Price
$22.43
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-07 | 2025-08-08 | 2025-06-13 | 2025-03-31 | 2024-11-11 | 2024-08-09 | 2024-05-14 | 2024-03-29 | 2023-11-13 | 2023-08-08 | 2023-05-15 | 2023-03-21 |
| Reported EPS | -0.84 | -0.7 | -0.56 | -0.8 | -0.5462 | -0.27 | -0.41 | -0.38 | -0.7 | -1.5537 | -2.01 | -2 |
| Estimated EPS | -0.46 | -0.68 | -0.6233 | -0.6343 | -0.41 | -0.31 | -0.39 | -0.29 | -0.95 | -2.9 | -1.91 | -2.22 |
| Surprise | -0.38 | -0.02 | 0.0633 | -0.1657 | -0.1362 | 0.04 | -0.02 | -0.09 | 0.25 | 1.3463 | -0.1 | 0.22 |
| Surprise Percentage | -82.6087% | -2.9412% | 10.1556% | -26.1233% | -33.2195% | 12.9032% | -5.1282% | -31.0345% | 26.3158% | 46.4241% | -5.2356% | 9.9099% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-16 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.79 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: CRVO
2026-01-28 13:53:22
CervoMed Inc. is dedicating its efforts to developing the first treatment for Lewy body dementia, the second most common progressive form of dementia. The company acknowledged World Lewy Body Dementia Day by highlighting the millions affected by this debilitating condition that impacts thinking, movement, behavior, and mood. Through ongoing research and development, CervoMed aims to achieve a significant breakthrough to improve the lives of those suffering from this illness.
2026-01-26 09:31:07
Analysts have given CervoMed Inc. (NASDAQ:CRVO) an average rating of "Moderate Buy" with a consensus 1-year price target of $22.17, despite the company reporting weak earnings and negative net margin in its last quarter. Insider trading activity shows significant buying, with management and other insiders accumulating shares, and institutional investors also adjusting their positions. CervoMed is trading near $6.28, having recently experienced insider purchases by CEO John J. Alam and Matthew Winton.
2026-01-16 13:57:21
Investing in biotech carries significant risks due to clinical trial failures, regulatory hurdles, and capital dilution, despite the potential for extraordinary returns if a drug proves successful. The article suggests that insider buying, particularly cash purchases by multiple insiders, can serve as a valuable signal, prompting further research into biotech companies like Summit Therapeutics (SMMT), Annexon (ANNX), and CervoMed (CRVO) as potential opportunities. However, investors are cautioned to manage risk through sensible position sizing and by understanding a company's cash runway.
2026-01-14 13:28:39
Zacks Research upgraded CervoMed (NASDAQ:CRVO) from a "strong sell" to a "hold" rating, contributing to the stock's consensus "Moderate Buy" rating with a target price of $21.86. Despite recent weak quarterly results and negative margins, insiders, including the CEO, have been actively purchasing shares, increasing their ownership to 35.4%, which may signal confidence in the company's future. CervoMed, a biotechnology company, focuses on developing treatments for age-related neurological disorders, with its lead drug candidate being neflamapimod.
2026-01-08 21:09:12
CervoMed Inc. has released an updated investor presentation on its website, summarizing its business, clinical studies, development plans, and financial position. The company explicitly stated that this presentation is not a formal SEC filing but may be used in investor interactions. TipRanks' AI Analyst, Spark, assesses CRVO as "Neutral" due to weak financial performance, despite positive Phase 2b clinical results providing some counterbalance to funding and execution risks.
2026-01-01 17:08:29
CervoMed Inc. (NASDAQ:CRVO) has received a "Moderate Buy" consensus rating from eleven brokerages, with an average 12-month price target of $21.86, significantly higher than its current share price of around $7.90. Despite recent weak financial results, insider purchases, including by the CEO, indicate confidence, with insiders now owning 35.40% of the stock. Institutional investors hold 25.15%, while analysts have issued various ratings from "sell" to "strong buy."
